ZOAR Zoar Limited

4.360USD-31.77%Mkt Cap: 784.80M USDP/E: —

Zoar Limited, a pharmaceutical company, focuses on the development and manufacture of active pharmaceutical ingredients. It also provides contract development and manufacturing services to pharmaceutical and biotechnolog…

Key Statistics

Company
Market Cap784.80M USD
Enterprise Value—
Revenue (TTM)—
Gross Profit111.18M USD
Net Income (TTM)77.67M USD
Revenue/Share—
Last Price4.360 USD
Fiscal Year End—
MR Quarter—
Employees—
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - General
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B—
EPS (TTM)—
EPS (Forward)—
52W Range
3.74521% of range6.720
52W High6.720 USD
52W Low3.745 USD
Profitability
Gross Margin17.06%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin11.92%
ROE18.70%
ROA13.18%
ROIC19.42%
ROCE22.13%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF623.00K USD
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt—
Net Debt/EBITDA—
Net Debt/FCF—
Balance Sheet
Debt/Equity0.04
Current Ratio—
Quick Ratio—
Book Value/Sh—
Cash/Share—
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.180.00M
Float—
Insiders—
Institutions—
Technical
SMA 506.390 (-31.8%)
SMA 2006.390 (-31.8%)
Beta—
S&P 52W Chg12.00%
Avg Vol (30d)36.08K
Avg Vol (10d)44.30K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—

About Zoar (NYSEAMERICAN: ZOAR)

›

Zoar (NYSEAMERICAN: ZOAR) is listed on NYSE American, where its shares trade in USD. It belongs to the Drug Manufacturers - General industry, part of the Healthcare sector.

The shares were at 4.360 USD on 19 November 2026. Its 52-week range is 3.745 USD to 6.720 USD: the price is 35.1% below the high and 16.4% above the low.

Its market capitalisation is 784.80M USD.

Zoar reports return on equity of 18.7% and an operating margin of 0.0%.

Its Piotroski F-score is 7 out of 9, a strong reading of its financial health.